QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.049262v1 306/1/407    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, C. Articles by Scatton, B. Search for Related Content PubMed PubMed Citation Articles by Cohen, C. Articles by Scatton, B.

NEUROPHARMACOLOGY

SSR591813, a Novel Selective and Partial ₄₂ Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation

Central Nervous System Research Department (C.C., O.E.B., F.G., A.W.L., S.J., B.B., J.L., P.A., A.C., A.O., O.C., C.V., A.G., G.P., P.G., P.S., B.S.), Sanofi-Synthelabo Research, Bagneux, France; and Molecular Biology (F.S., F.B., D.G.) and Pharmacology Department (D.C.), Sanofi-Synthelabo Research, Rueil-Malmaison, France

(5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine (SSR591813) is a novel compound that binds with high affinity to the rat and human ₄₂ nicotinic acetylcholine receptor (nAChR) subtypes (K_i = 107 and 36 nM, respectively) and displays selectivity for the ₄₂ nAChR (K_i, human ₃₄ > 1000, ₃₂ = 116; ₁₁ > 6000 nM and rat ₇ > 6000 nM). Electrophysiological experiments indicate that SSR591813 is a partial agonist at the human ₄₂ nAChR subtype (EC₅₀ = 1.3 µM, IA =19% compared with the full agonist 1,1-dimethyl-4-phenyl-piperazinium). In vivo findings from microdialysis and drug discrimination studies confirm the partial intrinsic activity of SSR591813. The drug increases dopamine release in the nucleus accumbens shell (30 mg/kg i.p.) and generalizes to nicotine or amphetamine (10–20 mg/kg i.p.) in rats, with an efficacy approximately 2-fold lower than that of nicotine. Pretreatment with SSR591813 (10 mg/kg i.p.) reduces the dopamine-releasing and discriminative effects of nicotine. SSR591813 shows activity in animal models of nicotine dependence at doses devoid of unwanted side effects typically observed with nicotine (hypothermia and cardiovascular effects). The compound (10 mg/kg i.p.) also prevents withdrawal signs precipitated by mecamylamine in nicotine-dependent rats and partially blocks the discriminative cue of an acute precipitated withdrawal. SSR591813 (20 mg/kg i.p.) reduces i.v. nicotine self-administration and antagonizes nicotine-induced behavioral sensitization in rats. The present results confirm important role for ₄₂ nAChRs in mediating nicotine dependence and suggest that SSR591813, a partial agonist at this particular nAChR subtype, may have therapeutic potential in the clinical management of smoking cessation.

Address correspondence to: Dr. C. Cohen, Central Nervous System Research Department, Sanofi-Synthelabo Research, 31 avenue Paul Vaillant-Couturier, 92220 Bagneux, France. E-mail: caroline.cohen{at}sanofi-synthelabo.com

This article has been cited by other articles:

				W. H. Frishman Smoking cessation pharmacotherapy Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 287 - 308. [Abstract] [PDF]

				S. L Zierler-Brown and J. A Kyle Oral Varenicline for Smoking Cessation Ann. Pharmacother., January 1, 2007; 41(1): 95 - 99. [Abstract] [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				E. K. Lambe, P. Olausson, N. K. Horst, J. R. Taylor, and G. K. Aghajanian Hypocretin and Nicotine Excite the Same Thalamocortical Synapses in Prefrontal Cortex: Correlation with Improved Attention in Rat J. Neurosci., May 25, 2005; 25(21): 5225 - 5229. [Abstract] [Full Text] [PDF]